ATTIVITA' ANTI-TUMORALE DELL' ALA-OMEGA-3

Maggiori informazioni sono disponibili alle pagine seguenti:

• OMEGA 3 Carcinoma Mammario
• OMEGA 3 Carcinoma Colorettale

Gli acidi grassi Omega-3, come l'acido alfa-Linolenico (ALA) e l'EPA, sono noti come agenti preventivi ed anticachettici.

Si ritiene che ciò sia dovuto a:
- azione inibitoria degli Omega 3 nei confronti della trasformazione dell'acido LA-Omega 6 in sostanze mitogene, come l'acido13-idrossioctadecadienoico (13-HODE).
- ostacolando l’attecchimento di cellule cancerogene ai tessuti sani e quindi l’invasività dei tumori.
- producendo dei composti perossidati che inibiscono la crescita cellulare e potenziano l’effetto di alcuni chemioterapici, (tassolo e cisplatino)

La relazione con gli acidi grassi Omega 6, rende evidente l'importanza di un'assunzione bilanciata degli acidi grassi essenziali Omega-3 ed Omega-6.

In tre studi francesi su 632 donne, è stata evidenziata una netta riduzione dell’incidenza del carcinoma mammario (-61/64%) in relazione all’aumento del contenuto di acidi grassi Omega 3 nel tessuto adiposo. (rapporto Omega 3/Omega 6 1:3 equivalente ad una dieta con 2,5 gr ALA-Omega 3 e 7,5 gr Omega 6, facilmente praticabile con VitalOil)

Studi su modelli evidenziano un effetto potenziante della Melatonina associata all'acido ALA-Omega 3 fornito ad un rapporto Omega-3 : Omega-6 di circa 1:1 e di potenziamento dell’effetto del tassolo. 

Molto frequentemente la comune dieta apporta 0,6-0,8 gr di ALA-Omega 3 ed il rapporto Omega 3/Omega 6 è prossimo all’1:10. VitalOil fornisce un rapporto ALA-Omega 3/LA-Omega 6 di 1:1 . Desiderando si può personalizzare la formula giungendo fino ad un rapporto Omega 3:Omega 6 di 3:2 (solo Blusterol). 

ABSTRACTS tratti da      

PubMed, a service of the National Library of Medicine, provides access to over 12 million MEDLINE citations back to the mid-1960's and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.

 Cancer Res 2000 Sep 15;60(18):5289-95

Mechanism for the antitumor and anticachectic effects of n-3 fatty acids.

Sauer LA, Dauchy RT, Blask DE.

Bassett Research Institute, Cooperstown, New York 13326, USA. lensauer@juno.com

Dietary intake of the n-6 fatty acid (FA) linoleic acid (LA) has a strong growth-promoting effect on many rodent tumors and human tumor xenografts grown in immunodeficient rodents. n-3 FAs such as alpha-linolenic and eicosapentaenoic acids (EPAs), which differ from LA and arachidonic acid, respectively, by only a single double bond in the n-3 position, are recognized cancer chemopreventive and anticachectic agents. Understanding how this seemingly small structural difference leads to such remarkable functional differences has been a challenge. In a previous study, we showed that LA uptake, [3H]thymidine incorporation into DNA, and total DNA content were decreased in tissue-isolated hepatoma 7288CTC perfused in situ with arterial blood containing alpha-linolenic acid, EPA, or docosahexaenoic acids. The Ki for the inhibition of LA uptake and [3H]thymidine incorporation by alpha-linolenic acid was 0.18 and 0.25 mM, respectively.

Here we show that the addition of alpha-linolenic acid or EPA to arterial blood inhibits tumor FA uptake, including LA, and the subsequent conversion of LA to the mitogen 13-hydroxyoctadecadienoic acid (13-HODE) in vivo and during perfusion in situ.

[3H]Thymidine incorporation during perfusion in situ was also inhibited. Addition of 13-HODE to the arterial blood reversed the inhibition of [3H]thymidine incorporation but had no effect on FA uptake. These two n-3 FAs also inhibited FA transport in inguinal fat pads in vivo and during perfusion in situ in fed (FA uptake) and fasted (FA release) rats. The effects of EPA and talinolenic acid on transport of saturated, monounsaturated, and n-6 polyunsaturated FAs in hepatoma 7288CTC and inguinal fat pads during perfusion in situ were reversed by the addition of forskolin (1 microM), pertussis toxin (0.5 microg/ml), or 8-bromo-cyclic AMP (10 microM) to the arterial blood. We conclude that the antitumor and anticachectic effects of n-3 FAs on hepatoma 7288CTC and inguinal fat pads in vivo result from an inhibition of FA transport. These inhibitions are mediated by a putative n-3 FA receptor via a Gi protein-coupled signal transduction pathway that decreases intracellular cyclic AMP. A specific decrease in LA uptake and its conversion to the mitogen 13-HODE causes the tumor growth inhibition.